Publications dans lesquelles il/elle collabore avec Fernando Arribas (8)

2023

  1. Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban

    Journal of comparative effectiveness research, Vol. 12, Núm. 3, pp. e220049

2022

  1. Outcomes and predictive value of the 2MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: The EMIR study

    Cardiology Journal, Vol. 29, Núm. 4, pp. 601-609

  2. Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry

    European heart journal. Cardiovascular pharmacotherapy, Vol. 9, Núm. 1, pp. 38-46

  3. Rivaroxaban for the prevention of outcomes in patients with atrial fibrillation in clinical practice: an indirect comparison of national and international registries

    Journal of comparative effectiveness research, Vol. 11, Núm. 16, pp. 1173-1184

  4. Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR study

    European Journal of Clinical Investigation

2021

  1. Comments on the 2020 ESC/EACTS guidelines for the management of atrial fibrillation

    Revista Espanola de Cardiologia, Vol. 74, Núm. 5, pp. 378-383

  2. Thromboembolic and bleeding events with rivaroxaban in clinical practice in Spain: Impact of inappropriate doses (the EMIR study)

    Journal of Comparative Effectiveness Research, Vol. 10, Núm. 7, pp. 583-593

2019

  1. Comentarios a la guía ESC/ESH 2018 sobre el diagnóstico y tratamiento de la hipertensión arterial

    Revista Espanola de Cardiologia, Vol. 72, Núm. 2, pp. 104-108